Click for articles

Ba, D. E. N. I. A. N., et al. Restoration of T cell depression and suppression of blood pressure in spontaneously hypertensive rats (SHR) by thymus grafts or thymus extracts. The Journal of Immunology 128.3 (1982): 1211-1216.

Bach JF. 
Thymic hormones. J Immunopharmacol. 1979;1(3):277-310. 

Balbi B, Valle MT, Oddera S, and others. 
Thymomodulin increases release of granulocyte-macrophage colony stimulating factor and of tumour necrosis factor in vitro. European Respiratory Journal. October 1992; volume 5, number 9, pages 1097-1103.

Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. 
Review of thymic hormones in cancer diagnosis and treatment. Int J
Immunopharmacol. 2000 Apr;22(4):261-73.

Bos, R. et al. 
Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell
repertoire.
 Cancer Res. 65, 6443–6449 (2005).

Cangemi, V.; Volpino, P.; D’Andrea, N.; Gentili, S.; Ippoliti, F.; Piat. G. 
Thymostimulin effect on the immune response in
neoplastic patients submitted to surgical treatment.
 Panminerva Medica 1993, 35:218-23.

Cohen MH, Chretien PB, Ihde DC, et al. 
Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small cell lung cancer. JAMA 1979;241:1813-5.

Fiocchi A, Borella E, Riva E, et al. 
Double-blind clinical trial for the evaluation of the therapeutical effectiveness of a calf thymusderivative (Thymomodulin) in children with recurrent respiratory infections. Thymus 1986; 8:331-9.

 

Fiorilli M, Sirianni MC, Pandolfi F, Quinti I, Tosti U, Aiuti F, Goldstein G. Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency. Clin Exp Immunol. 1981 Aug; 45(2): 344-51.

Garbin F, Eckert K, Buttner P, Garbe C, Czarnecki J, Maurer H. 
The influence of the thymic preparation thymex-L on deficient antitumor-activity of monocytes from melanoma patients in-vitro. Oncol Rep. 1995 May;2(3):469-72.

Goldstein AL, Thurman GB, Rossio JL, Costanzi JJ. 
Immunologic reconstitution of patients with primary immunodeficiency diseases and cancer after treatment with thymosin. Transplant Proc. 1977 Mar;9(1):1141-4.

Goldstein AL. The Gordon Wilson lecture. 
The history of the development of thymosin: chemistry, biology and clinical
applications.
 Trans Am Clin Climatol Assoc. 1977;88:79-94.

Incefy GS, Boumsell L, Kagan W, Goldstein G, Sousa MD, Smithwick E, O’Reilly R, Good RA. 
Enhancement of T lymphocyte differentiation in vitro by thymic extracts and purified polypeptides in severe combined immunodeficiency diseases. Trans Assoc Am Physicians. 1975;88:135-45.

Incefy GS, O’Reilly RJ, Kapoor N, Iwata T, Good RA. 
In vitro differentiation of human marrow T cell precursors by thymic
factors in severe combined immunodeficiency.
 Transplantation. 1981 Oct;32(4):299-305.

Kouttab, N.M.;Prada, M.; Cazzola, P. 
Thymomodulin: biological properties and clinical applications. Medical Oncol. & Tumor Pharmacother. 1989, 6:5.

Lantero S, Oddera S, Silvestri M, Ottolini V, Sacco O, and Rossi GA. Division of Pneumology, G. Gaslini Institute, Genoa, Italy.

Thymomodulin enhances phagocytic and intracellular killing activities of polymorphonuclear leucocytes without increasing release of chemotactic factors. Monaldi Arch. Chest Dis. 1993; volume 48, number 1, pages 29-33.

Liberati AM, Ballatori E, Fizzotti M, et al. 
A randomized trial to evaluate the immunorestorative properties of thymostimulin in
patients with Hodgkin's disease in complete remission.
 Cancer Immunol.Immunother. 1988;26(1):87-93.

Low TL, Thurman GB, Chincarini C, McClure JE, Marshall GD, Hu SK, Goldstein AL. 
Current status of thymosin research:  evidence for the existence of a family of thymic factors that control T-cell maturation. Ann N Y Acad Sci. 1979;332:33-48.

Macchiarini P, Danesi R, Del Tacca M, Angeletti CA. 
Effects of thymostimulin on chemotherapy-induced toxicity and long-term survival in small cell lung cancer patients. Anticancer Res 1989;9:193-6.

Naylor, Paul H., and Milton G. Mutchnick. 
Thymus-derived peptides in the treatment of viral chronic hepatitis. Digestive Diseases 14.6 (1996): 362-370.

Skotnicki, A.B. 
Therapeutic application of calf thymus extract TFX. Medical Oncol. & Tumor Pharmacother. 1989, 6:31.

Terrizzi A, Di Somma C, Dato D, Sandri MT, Cazzola P, and Berti Riboli E. 
Thymomodulin prevents post-operative
immunodepression measured by means of skin tests.
 International Journal of Immunotherapy. 1988; volume 4, number 3, pages 193-198.

Twomey, J.J. and Kouttab, N.N.L. 
Selected phenotypic induction of null lymphocytes from mice with thymic and nonthymic agents. Cell Immun. 1982, 72:186.

Vucković-Dekić LJ1, Susnjar S, Stanojević-Bakić N, Rajner L, Frim O. 
The protective activity of Thymex L against
radiotherapeutically-induced cellular immunodepression in lung cancer patients.
 Neoplasma. 1992;39(3):171-6.

Wolf E, Milazzo S, Boehm K, Zwahlen M, Horneber M. 
Thymic peptides for treatment of cancer patients. Cochrane Database Syst Rev. 2011 Feb 16; (2):CD003993. Epub 2011 Feb 16.

202 Spring Street | Marion, MA  02738 | info@brmi.online | Tel: 508.748.0816 | Fax: 508.748.1976

  • Facebook
  • LinkedIn
  • YouTube
  • Twitter

THE CONTENT ON THIS SITE IS PRESENTED IN SUMMARY FORM, IS GENERAL IN NATURE, AND IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY; IT IS NOT ADVICE, NOR SHOULD IT BE TREATED AS SUCH. If you have any healthcare-related concerns, please call or see your physician or other qualified healthcare provider. This site is NOT intended to be a substitute for a healthcare provider’s consultation: NEVER DISREGARD MEDICAL ADVICE OR DELAY IN SEEKING IT BECAUSE OF SOMETHING YOU HAVE SEEN ON THIS SITE. We make no representations, nor any warranties, nor assume any liability for the content herein; nor do we endorse any particular product, provider, or service.

© 2017-2019 Dr. James Odell, ND, OMD, L.Ac.